Cervical intraepithelial neoplasia - Pipeline Insight, 2021

May 2021 | 60 pages | ID: C3A2CBAF34D5EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight’s, “Cervical intraepithelial neoplasia – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Cervical intraepithelial neoplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cervical intraepithelial neoplasia Understanding

Cervical intraepithelial neoplasia: Overview

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is a precancerous condition in which abnormal cells grow on the surface of the cervix. Cervical intraepithelial neoplasia results from HPV infection within cervical cells. These changes, especially in young women, commonly revert to normal cells due to an intact immune response and rapid turnover of cells on the cervix. Cervical intraepithelial neoplasia may be classified according to how much epithelial tissue is affected: Low-grade neoplasia (CIN 1) refers to dysplasia that involves about one-third of the thickness of the epithelium, CIN 2 refers to abnormal changes in about one-third to two-thirds of the epithelial layer, CIN 3 (the most severe form) describes a condition that affects more than two-thirds of the epithelium. About 60% of CIN-1 will regress to normal after 1 year. Women with CIN-2 and CIN-3 are at high risk for developing invasive cancer, although the average time for progression is still several years. In most instances, dysplastic lesions of the cervix are not visible to the naked eye, and it is the pap smear which detects abnormalities requiring further evaluation. Colposcopy with directed biopsy is the preferred method for evaluation of an abnormal pap smear result. In the case of moderate and severe CIN, treatment focuses on the removal of abnormal cells that might become cancerous.

'Cervical intraepithelial neoplasia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cervical intraepithelial neoplasia pipeline landscape is provided which includes the disease overview and Cervical intraepithelial neoplasia treatment guidelines. The assessment part of the report embraces, in depth Cervical intraepithelial neoplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cervical intraepithelial neoplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cervical intraepithelial neoplasia R&D. The therapies under development are focused on novel approaches to treat/improve Cervical intraepithelial neoplasia.

Cervical intraepithelial neoplasia Emerging Drugs Chapters

This segment of the Cervical intraepithelial neoplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cervical intraepithelial neoplasia Emerging Drugs

• VGX-3100: Inovio Pharmaceuticals

INOVIO’s product candidate VGX-3100 is designed to significantly increase T cell immune responses against the E6 and E7 antigens of HPV types 16 and 18 that are present in both precancerous and cancerous cells transformed by these HPV types. INOVIO’s lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it eliminated high grade dysplasia in nearly 50% of women in a Phase 2b clinical trial; in 80% of those whose high grade dysplasia was eliminated, the HPV infection was also cleared by VGX-3100.

• BLS-ILB-E710c: Bioleaders Corporation

BLS-ILB-E710c is an orally available Lactobacillis casei (L. casei)-based vaccine expressing the human papillomavirus (HPV) type 16 isoform E7 protein linked to the poly-gamma-glutamate synthetase complex gene PgsA, with potential immunostimulating activity. Upon oral administration, the expressed HPV 16 E7 may stimulate the immune system to mount a mucosal cytotoxic T-lymphocyte (CTL) response against HPV 16 E7-expressing tumor cells. A Phase 2b Trial is ongoing to evaluate the efficacy and safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3).

Further product details are provided in the report..

Cervical intraepithelial neoplasia: Therapeutic Assessment

This segment of the report provides insights about the different Cervical intraepithelial neoplasia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cervical intraepithelial neoplasia

There are approx. 10+ key companies which are developing the therapies for Cervical intraepithelial neoplasia. The companies which have their Cervical intraepithelial neoplasia drug candidates in the most advanced stage, i.e. Phase III include, Inovio Pharmaceuticals.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cervical intraepithelial neoplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cervical intraepithelial neoplasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cervical intraepithelial neoplasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cervical intraepithelial neoplasia drugs.

Cervical intraepithelial neoplasia Report Insights

• Cervical intraepithelial neoplasia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cervical intraepithelial neoplasia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cervical intraepithelial neoplasia drugs?
• How many Cervical intraepithelial neoplasia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cervical intraepithelial neoplasia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cervical intraepithelial neoplasia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cervical intraepithelial neoplasia and their status?
• What are the key designations that have been granted to the emerging drugs?

Contents

Introduction
Executive Summary
Cervical intraepithelial neoplasia: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Cervical intraepithelial neoplasia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Cervical intraepithelial neoplasia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cervical intraepithelial neoplasia Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
VGX-3100: Inovio Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
  Comparative Analysis
BLS-ILB-E710c: Bioleaders Corporation
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Early stage products (Phase I/II)
  Comparative Analysis
VB10.16: Vaccibody
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Inactive Products
  Comparative Analysis
Cervical intraepithelial neoplasia Key Companies
Cervical intraepithelial neoplasia Key Products
Cervical intraepithelial neoplasia- Unmet Needs
Cervical intraepithelial neoplasia- Market Drivers and Barriers
Cervical intraepithelial neoplasia- Future Perspectives and Conclusion
Cervical intraepithelial neoplasia Analyst Views
Cervical intraepithelial neoplasia Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cervical intraepithelial neoplasia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Cervical intraepithelial neoplasia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products